ACT-389949

• Description:

  ACT-389949 is a first-in-class, potent and selective and agonist of formyl peptide receptor type 2 (FPR2) /Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2/ALX internalization into monocytes. ACT-389949 has potential for the treatment of inflammatory disorders[1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H302

• Target:

  Formyl Peptide Receptor (FPR)

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/act-389949.html

• Purity:

  99.96

• Solubility:

  DMSO : 10 mg/mL (ultrasonic; adjust pH to 1 with HCl)

• Smiles:

  O=C (C1=C (C2=CC=CC (C) =C2) OC (C) =N1) NC3=NN (CC4=NC (C (F) (F) C) =CO4) N=C3

• Molecular Formula:

  C20H18F2N6O3

• Molecular Weight:

  428.39

• Precautions:

  H302

• References & Citations:

  [1]Stalder AK, et al. Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949. Br J Clin Pharmacol. 2017 Mar;83 (3) :476-486.|[2]Lind S, et al. Functional and signaling characterization of the neutrophil FPR2 selective agonist Act-389949. Biochem Pharmacol. 2019 Aug;166:163-173.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  1258417-54-7